To evaluate the peripheral T-cell activation phenotype as a biomarker for clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Latest Information Update: 08 Dec 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics
Most Recent Events
- 08 Dec 2023 New trial record
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress